The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Larger Will The Oncolytic Virus Therapy Market Become By 2030 Compared To 2026?
The oncolytic virus therapy market has experienced significant expansion in recent years. Its valuation is projected to increase from $0.23 billion in 2025 to $0.29 billion in 2026, driven by a compound annual growth rate (CAGR) of 23.7%. This historical growth can be attributed to several contributing factors, such as the advancement of hsv- and adenovirus-based oncolytic therapies, early-stage clinical trials focused on melanoma and breast cancer, heightened interest from cancer research institutes, increased government funding allocated to virotherapy research, and a rise in collaborations between biotech companies and academic institutions.
The oncolytic virus therapy market is projected to experience substantial expansion in the coming years. This market is forecast to reach $0.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.7%. This anticipated growth is driven by several factors, including a heightened demand for genetically engineered oncolytic viruses, their increasing application in treating lung, prostate, and brain cancers, the proliferation of specialized clinics and hospitals providing virotherapy, greater investment in combined and novel virus therapies, and the expansion of clinical trial facilities within developing regions. Key developments expected during this period involve the growing integration of AI and big data into oncolytic virus research, enhanced utilization of genomics and precision medicine for designing therapies, broader deployment of digital platforms for overseeing clinical trials, increased automation in the manufacturing and quality control of viruses, and the expanding use of IoT-based systems for tracking virus storage and distribution.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp
Which Strategic Drivers Are Supporting The Oncolytic Virus Therapy Market Development?
The oncolytic virus therapy market is anticipated to expand due to the increasing prevalence of cancer cases. Cancer refers to a group of diseases marked by the uncontrolled multiplication and spread of abnormal cells throughout the body. Oncolytic virus therapy provides the ability to selectively target and destroy cancer cells while also stimulating an immune response against the tumor, offering a dual mechanism of action for effective cancer treatment. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising occurrence of cancer cases is driving the growth of the oncolytic virus therapy market.
Which Segment Divisions Form The Structure Of The Oncolytic Virus Therapy Market?
The oncolytic virus therapy market covered in this report is segmented –
1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types
2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses
3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer
4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes
Subsegments:
1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches
2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies
3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches
4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies
5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments
6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms
What Trends Are Driving Changes In The Oncolytic Virus Therapy Market?
Leading firms within the oncolytic adenovirus market are prioritizing combination treatments like VCN-01, a strategy that merges oncolytic virotherapy with chemotherapy to boost tumor targeting and elevate therapeutic results. This VCN-01 is an oncolytic adenovirus specifically designed to infect and eradicate cancer cells, simultaneously amplifying the efficacy of chemotherapy. As an illustration, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology firm, disclosed that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation (FTD) to its primary candidate, VCN-01. The designation specifically applies to VCN-01 when administered alongside gemcitabine and nab-paclitaxel to treat metastatic pancreatic adenocarcinoma. VCN-01 functions as an oncolytic adenovirus by targeting and reproducing within tumor cells, thereby aiding in the degradation of the tumor stroma, which represents a significant barrier to successful cancer therapy.
Which Companies Are Engaged In The Oncolytic Virus Therapy Market Environment?
Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.
Access The Complete Oncolytic Virus Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report
Which Region Stands As The Largest Contributor To The Oncolytic Virus Therapy Market?
North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Oncolytic Virus Therapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp
Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company
Clinical Nutrition For Cancer Care Global Market Report 2026
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model